India TB Burden: Why Health Groups Demand Data Clarity

The global healthcare community recently received updated epidemiology data from the World Health Organization. While the report highlights notable progress in mortality reduction, the persistent India TB burden continues to demand urgent attention. India accounts for roughly 25% of global tuberculosis infections and nearly 23% of disease-related deaths. Consequently, public health advocacy network Jan Swasthya Abhiyan India has formally petitioned health authorities for systemic accountability. They emphasize that clinical progress requires transparent epidemiology reporting alongside dependable supply chains for life-saving therapeutics.
Examining the India TB Burden and Surveillance Gaps
Recent evaluations show a 38% reduction in national TB mortality between 2015 and 2025. Furthermore, India achieved an impressive 94% treatment success rate among patients with drug-susceptible tuberculosis. However, public health experts point out that disease incidence estimates remain contentious. In the latest global report, the World Health Organization kept India’s incidence estimates under technical review. This review awaits statistical calibration from a 50-district sentinel surveillance survey. Therefore, clinicians currently lack definitive, granular case burden figures across several vulnerable populations. Additionally, the Central TB Division has not refreshed the public annual report beyond 2024. Because updated district-level data remain unpublished, independent researchers struggle to measure local transmission patterns accurately.
Supply Chain Disruptions and Medicine Depletion
Beyond epidemiology disputes, healthcare providers face recurrent drug shortages on the ground. Specifically, investigative findings revealed severe interruptions in central anti-TB medicine supplies. Procurement records indicate that intensive-phase fixed-dose combination supplies fell 56.5% during 2023. Meanwhile, continuation-phase medication distribution declined by 23% over the same period. In addition, auditor investigations exposed grave supply chain mismanagement. The Comptroller and Auditor General noted that expired medicines worth ₹40.75 crore accumulated across five central depots. Such systemic logistical failures directly endanger patient adherence and promote drug resistance. When patients miss therapy doses, the risk of multi-drug-resistant strains rises substantially.
Recommended Measures for Sustainable TB Elimination
To address these operational barriers, advocacy groups propose several systemic reforms. First, health authorities should perform an independent, nationwide audit of anti-TB drug availability. Next, health departments must publish monthly disclosures detailing stock levels and stock-out days at local treatment centers. Furthermore, program managers need real-time digital monitoring to verify medicine stocks across primary facilities. Clinicians also emphasize maintaining mandatory buffer stocks to prevent sudden treatment gaps. Ultimately, achieving complete disease elimination requires uncompromised public accountability alongside clinical excellence.
Frequently Asked Questions
Q1: What proportion of the global TB burden does India carry?
India accounts for approximately 25% of all tuberculosis cases and 23% of tuberculosis deaths globally, representing the highest burden worldwide.
Q2: Why did the WHO keep India's 2025 TB incidence estimates under review?
The WHO placed the estimates under review to conduct technical calibration with data from India's 50-district sentinel surveillance survey.
Q3: How do anti-TB medication shortages impact clinical patient outcomes?
Treatment interruptions caused by drug shortages increase treatment failure rates, elevate relapse chances, and significantly raise the risk of drug-resistant tuberculosis.
References
- Public Health network flags high TB burden despite mortality decline, seekstransparency in reporting - ETHealthworld
- World Health Organization. Global Tuberculosis Report 2026. Geneva: World Health Organization; 2026.
- Central TB Division, Ministry of Health and Family Welfare. India TB Report 2024. New Delhi: Government of India; 2024.
- Comptroller and Auditor General of India. Performance Audit on National Tuberculosis Elimination Programme, Report No. 8 of 2024. New Delhi: CAG; 2024.




